Efficacy and Safety of F-18 FPCIT PET in Parkinson's Disease and Essential Tremor Patients

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether F-18 FPCIT is effective and safe radiopharmaceutical for the objective diagnosis of Parkinson's disease.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Asan Medical Center

Criteria

Inclusion Criteria:

Parkinson's disease

• Male or female with age over 40 years

• Clinical diagnosis of Parkinson's disease

• Ability to give informed consent

Essential tremor

• Male or female with age over 40 years

• Clinical diagnosis of Essential tremor

• Ability to give informed consent

Healthy volunteers

• Male or female with age over 40 years

• No any symptoms or sign suggesting Parkinson's disease or essential tremor

• Ability to give informed consent

Exclusion Criteria:

Parkinson's disease and essential tremor

• Current pregnancy and breast feeding

• Current or past medical history of cardiac and neuropsychiatric disease

• Clinical evidence of dementia

• Inability to hold antiparkinsonian medication

• History of surgical therapy for tremor

• Severe or unstable medical or psychiatric condition

• Medication affecting CNS in last 6 months(e.g. CNS stimulants, sympathomimetics)

• Prior participation in other research protocol within 30 days

Healthy volunteers

• Current pregnancy and breast feeding

• Current or past medical history of cardiac and neuropsychiatric disease

• Severe or unstable medical or psychiatric condition

• Drug abuse or medication affecting CNS (e.g. CNS stimulants, sympathomimetics) within 6 months

• Prior participation in other research protocol within 30 days